| Dr Jessica B Ton, MD | |
|
2000 Medical Pkwy Ste 309, Annapolis, MD 21401-3745 | |
| (443) 481-3493 | |
| Not Available |
| Full Name | Dr Jessica B Ton |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 2000 Medical Pkwy Ste 309, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992061493 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | D0087344 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| Doctors' Community Hospital | Lanham, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
News Archive
In a series about the health care systems in five countries, the NewsHour examines the Netherlands and its massive health care overhaul. "When the Netherlands redesigned its national health care system in 2006, there were three main goals: continue universal coverage, unleash competition between private insurers, and keep down costs for the long run.
It's hard to stay on the wagon when you're depressed, according to a new study of problem drinkers.
Blood tests for ‘biomarkers' such as cholesterol and inflammation could predict whether you will be disabled in five years – according to research from the University of East Anglia.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
Columbia Engineering researchers, led by Dimitris Anastassiou, Charles Batchelor Professor in Electrical Engineering and member of the Columbia Initiative in Systems Biology, have developed a new computational model that is highly predictive of breast cancer survival.
› Verified 6 days ago
| Entity Name | Luminis Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073580205 PECOS PAC ID: 2860447315 Enrollment ID: O20050317000146 |
News Archive
In a series about the health care systems in five countries, the NewsHour examines the Netherlands and its massive health care overhaul. "When the Netherlands redesigned its national health care system in 2006, there were three main goals: continue universal coverage, unleash competition between private insurers, and keep down costs for the long run.
It's hard to stay on the wagon when you're depressed, according to a new study of problem drinkers.
Blood tests for ‘biomarkers' such as cholesterol and inflammation could predict whether you will be disabled in five years – according to research from the University of East Anglia.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
Columbia Engineering researchers, led by Dimitris Anastassiou, Charles Batchelor Professor in Electrical Engineering and member of the Columbia Initiative in Systems Biology, have developed a new computational model that is highly predictive of breast cancer survival.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica B Ton, MD 2000 Medical Pkwy Ste 200, Annapolis, MD 21401-3744 Ph: (443) 481-3493 | Dr Jessica B Ton, MD 2000 Medical Pkwy Ste 309, Annapolis, MD 21401-3745 Ph: (443) 481-3493 |
News Archive
In a series about the health care systems in five countries, the NewsHour examines the Netherlands and its massive health care overhaul. "When the Netherlands redesigned its national health care system in 2006, there were three main goals: continue universal coverage, unleash competition between private insurers, and keep down costs for the long run.
It's hard to stay on the wagon when you're depressed, according to a new study of problem drinkers.
Blood tests for ‘biomarkers' such as cholesterol and inflammation could predict whether you will be disabled in five years – according to research from the University of East Anglia.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
Columbia Engineering researchers, led by Dimitris Anastassiou, Charles Batchelor Professor in Electrical Engineering and member of the Columbia Initiative in Systems Biology, have developed a new computational model that is highly predictive of breast cancer survival.
› Verified 6 days ago
Richard G. Welch, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2000 Medical Pkwy, Ste 304, Annapolis, MD 21401 Phone: 410-573-9530 Fax: 410-573-9569 | |
Monica B Jones, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2000 Medical Pkwy Ste 200, Annapolis, MD 21401 Phone: 443-481-3493 Fax: 443-481-6705 | |
Dr. Joy'el B Ballard, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2000 Medical Pkwy, Ste. 304, Annapolis, MD 21401 Phone: 410-573-9530 Fax: 410-573-9568 | |
Dr. Christine Ajjan Laky, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 185 Harry S Truman Pkwy Ste 120, Annapolis, MD 21401 Phone: 410-224-4442 Fax: 410-224-8898 | |
Margaret Jessica Keith, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2003 Medical Pkwy, Annapolis, MD 21401 Phone: 410-571-9700 | |
Elizabeth T. Greeley, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 820 Bestgate Rd, Suites 2c & 2d, Annapolis, MD 21401 Phone: 410-224-4442 Fax: 410-224-8898 | |
Mark L. Repka, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2000 Medical Pkwy, Ste 304, Annapolis, MD 21401 Phone: 410-573-9530 Fax: 410-573-9569 |